Newpath Partners

Newpath Partners Research Investment Thesis Founded in 2018 by physician-scientist Thomas Cahill, M.D., Ph.D., Newpath Partners operates on a distinctive thesis: venture capital can do more than fund companies—it can create them from the ground up. The firm specializes in building biotechnology companies in partnership with leading academic scientists, focusing on breakthrough biology platforms with the potential to address the greatest unmet needs in medicine. This company-formation model distinguishes Newpath from traditional biotech VCs, providing not just capital but operational expertise, board experience, and deep scientific credibility. The firm's philosophy is guided by a simple ethos: "do the right thing and good things will happen." This commitment to scientific rigor and founder partnership has resulted in an unusually high rate of company formation and exits per investment professional, with a lean team managing approximately $350+ million in assets under management. Sector and Stage Focus Newpath Partners focuses exclusively on the life sciences and biotechnology sector, with particular emphasis on: Core Focus Areas: Gene Editing Technologies : Including prime editing, base editing, and epigenetic editing approaches Regenerative Medicine : Cell therapy, tissue engineering, and regenerative approaches Drug Discovery Platforms : Novel therapeutic modalities and discovery technologies Breakthrough Biology Platforms : Emerging therapeutic approaches with high scientific novelty Therapeutic Focus: Central Nervous System (CNS) disorders (depression, neurological conditions) Genetic and inherited diseases Obesity and metabolic disease Oncology (cancer therapeutics) Autoimmune conditions Gene and cell therapies Investment Stage and Check Size Newpath Partners primarily invests at the Series A stage with substantial check sizes, leveraging their company-formation model. The fund also participates in seed rounds and selective Series B follow-ons. Stage Distribution: Series A : Primary focus (~60% of activity) Seed : Strategic seed-stage company formations Series B : Selective follow-on investments Check Sizes: Series A : Typically $50M-$200M+ (leading or co-leading rounds) Seed : $10M-$50M for company formations Follow-ons : Substantial reserves for pro-rata follow-ons The firm's largest recent investment was a $100M Series C in Autobahn Therapeutics (July 2024), demonstrating their appetite for significant capital deployment in strong companies. Lead Tendency and Decision Process Newpath Partners operates as a lead investor . The firm frequently leads Series A rounds for companies it has helped form or guided from seed stage. When investing in external companies, Newpath takes significant ownership stakes and typically assumes board seats or close advisory roles. Decision Process: Partnership-based approach with scientific founders Investment committee model involving both business and scientific expertise Close collaboration with founder teams and academic partners Multi-month evaluation periods typical for transformational science High bar for scientific novelty and founder quality Timeline: Typically 2-3 months from initial introduction to investment decision, though complex scientific evaluations can extend this period. Team Structure and Expertise Newpath Partners operates a lean, highly specialized team with deep scientific and medical expertise. Leadership includes Thomas Cahill (Founder, MD/PhD), Daniel Yadegar (Co-Founder, MD), Tom Thomas (PhD trained cancer biologist), Ben Lewis (Partner), and AJ Ferraro (Principal). Recent Activity and Fund Status Newpath Partners is actively deploying capital from Fund II and Fund III. Recent notable investments: August 27, 2025 : $30M Series A in Leal Therapeutics July 25, 2024 : $100M Series C lead in Autobahn Therapeutics July 2024 : Participated in $100M Series C in AviaDo Bio April 18, 2024 : $290M Seed/Series A in Metsera 2023 : $50M Series A in Magnet Biomedicine Fund Status : Actively deploying with strong pipeline and momentum. Fund II is in mature deployment phase while Fund III is establishing initial positions. Portfolio Companies Newpath has built a substantial portfolio of 13+ companies across breakthrough biology platforms and therapeutic modalities. Notable portfolio companies include Prime Medicine, Chroma Medicine, Autobahn Therapeutics, Metsera, Orbital Therapeutics, Magnet Biomedicine, Eledon Pharmaceuticals, Exo Therapeutics, nChroma Bio, Neumorat Therapeutics, Leal Therapeutics, YourBio Health, and AERA Therapeutics. Key Differentiators Company Formation : Unique model of building companies from academic discoveries Scientific Team : Physician-scientist leadership rather than business-school VCs Operational Support : Beyond capital, provides governance and strategic direction Academic Partnerships : Direct relationships with leading research institutions Track Record : High rate of company formations and exits per investment professional Boston Positioning : Access to premier biotech and academic ecosystem